



**ON THE FRONT LINE™
AGAINST INFLUENZA**

DAVID ROSS, VP COMMERCIAL OPERATIONS
NORTH AMERICA



OUR PURPOSE

Influenza can kill.

We believe it shouldn't be that way.

We exist to transform influenza protection.



2 | ON THE FRONT LINE



INCREASING IMMUNIZATION RATES AND IMPROVING VACCINE EFFECTIVENESS UNITES ALL OF US IN THE FIGHT AGAINST INFLUENZA

THE WASHINGTON POST
By Lena H. Sun
October 25, 2018
Drop in adult flu vaccinations may be factor in last season's record-breaking deaths, illnesses

ABC NEWS
LIVE SHOWS
CDC Predicts Flu Vaccine Will Be More Effective Than Last Year
Last year's vaccine was less effective after a flu strain mutated.
By GILLIAN MOHNEY Sep 18, 2015 11:26 AM


CBS EVENING NEWS
By MARK STRASSMANN CBS NEWS February 1, 2018, 6:35 PM
Flu vaccine less than 20 percent effective against H3N2 strain, researchers say

STAT
HEALTH
Flu vaccine is only moderately protective this year, CDC says
By HELEN BRANDWELL @helenbrandwell / FEBRUARY 16, 2017

CNN Health • Food • Fitness • Wellness • Parenting • Live Longer
CDC: Flu shot less effective this year because current virus has mutated
By Debra Goldschmidt and Jen Christensen, CNN
Updated 11:11 AM ET, Wed December 10, 2014

Seqirus
A CSL COMPANY

WHILE VACCINATION REMAINS THE BEST PROTECTION AGAINST INFLUENZA, VARYING VACCINE EFFECTIVENESS ERODES PUBLIC CONFIDENCE



4 | ON THE FRONT LINE

References:
1. Centers for Disease Control and Prevention. Seasonal influenza vaccine effectiveness, 2004-2018. <https://www.cdc.gov/flu/professionals/vaccina-to-ri/efctiv-ness-studies.htm>. Updated September 25, 2018. Accessed May 1, 2019.

Seqirus
A CSL COMPANY

SEQIRUS SUPPORTS THE WHO'S EFFORTS TO IMPROVE VACCINE EFFECTIVENESS THROUGH INCREASED DATA ANALYSIS


CIDRAP
WHO changes H1N1 flu vaccine strain, punts on H3N2

Filed Under: **Influenza Vaccines**
 Lisa Schnirring | News Editor | CIDRAP News | Feb 21, 2019

CIDRAP
WHO reveals delayed pick for H3N2 flu vaccine strain

Filed Under: **Influenza Vaccines**
 Lisa Schnirring | News Editor | CIDRAP News | Mar 21, 2019

References:
 1. IPMA. Statement on influenza vaccine supply in the 2019-20 Northern Hemisphere season, 2004-2018. <https://www.ipma.org/resources/controls/state-matters-on-influenza-vaccine-supply-in-the-2019-20-northern-hemisphere-season/>. Updated March 21, 2019. Accessed April 30, 2019.



How do we optimize H3N2 manufacturing yields and gain access to reagents in a shorter window of time?



How do we mitigate vaccine supply bottlenecks?



How do we collaborate to ensure Immunization Campaigns aren't negatively impacted?



ROBUST MANUFACTURING

SUPPLY UPDATE: SEQIRUS PLANS TO SUPPLY 50+ MILLION DOSES ACROSS 3 BRANDS



AGE	DESCRIPTION	PRESENTATION
65+ years	Egg-based inactivated trivalent influenza vaccine adjuvanted with MF59®	PFS
4+ years	Cell-based inactivated quadrivalent influenza vaccine	PFS, MDV
6+ months	Egg-based inactivated quadrivalent influenza vaccine	PFS, MDV

6 | ON THE FRONT LINE

Abbreviations: PFS, prefilled syringe; MDV, multidose vial.
 Note: The PFS presentation is preservative free.



WE ALL HAVE A ROLE IN CHANGING THE PARADIGM...

New Technologies



Strain Selection



Advocacy & Policy



Research & Development



Disease Surveillance



Education & Best Practice Sharing



Robust Manufacturing




Real World Evidence

Seqirus
A CSL COMPANY

INNOVATIVE TECHNOLOGIES

TECHNOLOGIES TO ADDRESS THE UNIQUE CHALLENGES OF THE INFLUENZA VIRUS



Cell-Based



Adjuvant

8 | ON THE FRONT LINE

Seqirus
A CSL COMPANY

**REAL WORLD
EVIDENCE**

AN EVOLVING TOOL TO INFORM INFLUENZA VACCINES DECISION MAKING



**Healthcare
Providers**



**Vaccine
Manufacturers**



**Clinical
Researchers**



**Policy Makers
& Regulators**

Seqirus
A CSL COMPANY